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Objective: Treatment of severe ulcerative colitis (UC)
is challenging. Although the efficacy of tacrolimus
(TAC) and infliximab (IFX) have been evaluated in
patients with severe UC, the safety and efficacy levels
of sequential therapies (TAC→IFX/IFX→TAC) in these
patients remain unclear. The aim of this study was to
assess short-term and long-term outcomes in patients
with severe UC treated with TAC and IFX.
Methods: From October 2001 to February 2014, 29
patients with consecutive severe UC treated with TAC
or IFX were retrospectively evaluated. Median follow-up
duration was 27 months (range 0.5–118 months). The
primary end point was short-term outcomes at 8 weeks
after induction of TAC (TAC group, n=22) or IFX (IFX
group, n=7). The secondary end point included long-
term outcomes and colectomy-free survival. The
clinical response was evaluated based on a partial
Mayo score.
Results: The clinical remission (CR) rate at 8 weeks in
the TAC and IFX groups was 63.6% and 71.4%,
respectively. In 13 of the 29 patients (10 in the TAC
group, 3 in the IFX group), sequential therapies were
used in their clinical courses. In 9 of these 13 patients
(6 in the TAC group, 3 in the IFX group), CR was
achieved and maintained by sequential therapies.
Overall cumulative colectomy-free survival was 79.3%
at 118 months.
Conclusions: TAC and IFX had similar effects on
remission induction in patients with severely active UC.
Sequential therapies could rescue patients with UC
who failed initial treatment with TAC or IFX. In clinical
practice, sequential therapies might be deliberately
performed.
INTRODUCTION
Ulcerative colitis (UC) is a chronic inﬂamma-
tory disorder of the colon characterised by
diarrhoea, bloody stool, abdominal pain,
fever, anaemia and weight loss.1
A recent study showed that 25% of patients
with UC experienced episodes of severe
colitis.2 Although introduction of intravenous
corticosteroids (CS) has modiﬁed the natural
history of severe acute relapse, approximately
30–40% of patients with UC are refractory to
steroid therapy, and without further medical
management these patients will require
emergency colectomy.3 Therefore, the devel-
opment of a second-line rescue therapy for
steroid-resistant cases remains an important
challenge. The calcineurin-inhibitor cyclo-
sporine (CsA) is an immunosuppressant that
inhibits T-cell-mediated production of
interleukin-2 (IL-2). CsA was ﬁrst shown to
be an effective rescue therapy for acute
Summary box
What is already known about this subject?
▸ Corticosteroid (CS) is a first-line therapy for
patients with severe ulcerative colitis (UC).
▸ Second-line rescue therapy using tacrolimus
(TAC) or infliximab (IFX) is considered for
severe UC cases refractory to CS.
▸ Data on the short-term and long-term outcomes
of patients with severe UC treated with TAC and
IFX are limited.
▸ The efficacy and safety levels of sequential ther-
apies (TAC→IFX or IFX→TAC) remain unclear.
What are the new findings?
▸ TAC and IFX had similar effects on remission
induction in patients with severe UC.
▸ Sequential therapies could avoid colectomy in
patients with severe UC refractory to initial treat-
ment with TAC or IFX.
▸ In our study, there were no serious adverse
events in the treatment with sequential therapies.
How might it impact on clinical practice in
the foreseeable future?
▸ Our data demonstrated that sequential therapies
could be considered for patients with severe UC
who failed to respond to initial treatment with
TAC or IFX.
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severe steroid-refractory UC in 1994.4 Recent studies
showed response rates to CsA ranging from 64% to
82%.4 5 Despite the beneﬁts of CsA treatment, it is asso-
ciated with signiﬁcant toxicity and adverse reactions, and
thus alternative agents are required.
Tacrolimus (TAC) is an immunosuppressive macrolide
isolated from Streptomyces tsukubaensis.6 TAC inhibits
the complexation of calcineurin with its respective cyto-
plasmic receptors, cyclophilin and FK-binding protein
12, both of which regulate calmodulin-dependent phos-
phatase activity, thereby interrupting the signal transduc-
tion pathway in T cells.7 Although TAC and CsA have
similar modes of action, TAC has a 30-fold to 100-fold
greater immunosuppressive effect in vitro and a 10-fold
to 20-fold greater effect in vivo than CsA, as well as more
reliable intestinal absorption, even in the presence of
gastrointestinal disease.8 A randomised controlled
trial and several case studies have demonstrated that
TAC is effective for inducing and maintaining remission
in patients with refractory UC.8–11 TAC is thus consid-
ered to be a promising therapeutic option for refractory
UC.
In the past 10 years, inﬂiximab (IFX), a monoclonal
antibody that binds free and membrane-bound tumour
necrosis factor α, has demonstrated efﬁcacy for UC. Its
superior efﬁcacy compared to placebo in moderate-
to-severe non-acute UC is well established based on UC
trials (ACT1 and ACT2), with a response rate between
61% and 69%.12
While the use of both TAC and IFX has been shown
to be effective and safe as rescue therapy, data directly
comparing the effects of these two agents on severe UC
are limited.13 14 In the present study, we reviewed a
series of patients with severe UC admitted consecutively
to our hospital from 2001 up to the present, who had
been treated with TAC or IFX.
METHODS
Patients
This was a retrospective single centre study in Kyoto
University Hospital. We reviewed the medical records of
all patients who received at least one IFX infusion or
TAC treatment for treatment of severe active UC.
The diagnosis of UC was conﬁrmed according to stan-
dardised criteria by prior clinical assessment, radiology,
endoscopy and histology. We used the same deﬁnitions
of steroid dependency and refractoriness as the
European Crohn’s and Colitis Organization consensus.15
According to the Montreal classiﬁcation, a disease event
was categorised as proctitis if present up to 15 cm from
the anal verge, as left-sided colitis if present up to but
not beyond the splenic ﬂexure, or as extensive colitis if
present beyond the splenic ﬂexure.16
From October 2001 to February 2014, all patients with
severe UC were treated with TAC or IFX at Kyoto
University Hospital. All patients with UC in this study
had severe disease activity with a Mayo score greater
than 10 and moderate-to-severe inﬂammation on sig-
moidoscopy, despite concurrent treatment with CS and/
or immunomodulators (IM).
Treatment regimens were as follows: TAC was adminis-
tered orally at an initial dose of 0.1 mg/kg/day or
was administered intravenously at an initial dose of
0.01 mg/kg/day, and the dose was adjusted to produce
whole blood trough levels of 10–15 ng/mL to induce
remission. IFX episodic therapy was deﬁned as a single
infusion of 5 mg/kg of IFX at induction, followed by
further infusion if necessary. Scheduled therapy was
deﬁned as intravenous infusions of IFX at a dose of
5 mg/kg at weeks 0, 2 and 6, followed by regular infu-
sions every 8 weeks thereafter. For patients who did not
respond to initial treatments either with TAC or IFX,
and those who had relapsed despite their response to
initial treatment, sequential therapies (TAC→IFX or
IFX→TAC) were performed under the global assessment
of physicians.17 We collected data on the demographics,
baseline characteristics of severe UC, previous and con-
comitant medications, clinical outcome and adverse
events of both treatments.
Informed consent for participation in this study, which
was approved by the institutional ethics committee, was
provided by all patients.
Clinical outcomes
To evaluate disease activity and response to both treat-
ments, a partial Mayo score18–20 was retrospectively
determined both before treatment and after 8 weeks of
treatment, as well as at the last follow-up visit. In Kyoto
University Hospital, we evaluate disease activity of all
patients with UC, at least on every 4-week visit after start-
ing their induction therapy, by the partial Mayo score.
Clinical remission (CR) was deﬁned as a partial Mayo
score of less than 3. Relapse was deﬁned as an increase
in the partial Mayo score to 3 or higher with additional
therapies required. Mucosal healing was deﬁned as
endoscopic Mayo score of 0. Short-term outcomes were
evaluated at 8 weeks after initiating TAC or IFX treat-
ment. Long-term outcomes were evaluated using data
from patients who were followed up for more than
6 months after TAC or IFX treatment. Moreover,
colectomy-free survival was evaluated in all 29 patients
with severe UC during the period from the time of their
initial treatments to the last follow-up visit.
Definition of cytomegalovirus reactivation
All patients were tested for colonic cytomegalovirus
(CMV) reactivation by immunohistochemistry and quan-
titative real-time PCR using colonic biopsy specimens
(mucosal PCR). Colonic biopsy specimens were obtained
from inﬂamed colonic mucosa, ﬁxed in formalin,
embedded in parafﬁn and stained with H&E, and immu-
nohistochemistry was performed using anti-CMV mono-
clonal antibodies (Dako Cytomation, Kyoto, Japan).21
Cases in which the CMV-DNA copy number was over
10 copies/μg DNA were deﬁned as positive for CMV
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reactivation. Cases in which CMV was detected by either
one of these methods were diagnosed with positive
colonic CMV reactivation.22
Assessment and statistics
The primary end point of this study was short-term
outcome at 8 weeks after induction of TAC or IFX.
Secondary end points included long-term outcome and
colectomy-free survival at 2014 after the initiation of treat-
ment. Moreover, we assessed the efﬁcacy and safety of the
sequential therapies (TAC→IFX or IFX→TAC) in patients
with UC refractory to the initial treatment. Cumulative
colectomy-free survival was assessed using the
Kaplan-Meir method. Comparisons of differences within
groups were performed using the Mann-Whitney U test
or Student t test, depending on the distribution.
Categorical data were compared by χ2 analysis. A p value




Clinical characteristics of all patients with severe UC are
shown in table 1. Median age at diagnosis of severe UC
was 34 years (range 19–69 years). Median disease dur-
ation before the induction therapy was 43 months (range
2–348 months). Median follow-up period was 27 months
(range 0.5–118 months). Of the 29 patients, 18 were men
and 11 were women. Of the 29 patients, 24 were hospita-
lised at the induction therapy. Median partial Mayo score
was 9 (range 8–9) and the endoscopic Mayo score was 3
(range 2–3). Of the 29 patients, 23 had extensive disease
type and the other 6 patients had left-sided disease. C
reactive protein level was 7.0 (0.1–27.1) mg/dL, haemo-
globin level was 10.3 (7.1–13.4) g/dL and serum albumin
level was 2.9 (1.7–4.9) g/dL. Regarding previous
response to CS, 14 of the 29 patients (48.3%) were refrac-
tory to CS, 11 (37.9%) were dependent on CS and the
remaining 4 patients (13.8%) were naïve to CS. As con-
comitant therapy with the induction therapy, except for
one patient who was allergic to 5-aminosalicylate (5-ASA),
the patients were all treated with 5-ASA. Prior to initiating
treatment with TAC or IFX, 16 of the 29 patients were
treated with CS (9 with intravenous CS and 7 with oral
CS). Median duration of treatment with systemic CS
before initiating TAC or IFX was 36 days (range 14–4200
days). At initiating treatment with TAC or IFX, CS had
already tapered off in 9 of the 29 patients. CS was not
used for these patients’ induction therapies because they
had previous histories of long-term use of CS. Despite
being naïve to CS in the remaining four patients, they
were not treated with CS because they refused it. Nine of
the 29 patients were treated with concomitant thiopurine
and 15 were treated with concomitant cytapheresis.
For the induction therapy, 22 of the 29 patients were
treated with TAC (TAC group) and the remaining 7
patients were treated with IFX (IFX group). The choice
of TAC or IFX treatment for the induction therapy was
conducted according to the primary physician’s decision
at that time. There were no signiﬁcant differences in the
clinical characteristics between the TAC and IFX groups.
Short-term outcomes
The clinical course of short-term outcomes of the 29
patients with severe UC is shown in ﬁgure 1. Of 22
patients in the TAC group, 14 achieved a CR at 8 weeks
after initiating TAC and 6 of the remaining 8 patients
could not achieve a CR, although they responded to
TAC. The remaining two patients did not respond to
TAC and required sequential therapy (switched to IFX)
within 8 weeks after initiating TAC. Of seven patients in
the IFX group, ﬁve achieved a CR at 8 weeks after initiat-
ing IFX, while one required sequential therapy
(switched to TAC). One patient who did not respond to
IFX resulted in a colectomy without sequential therapy.
The CR rate at 8 weeks from initiating TAC or IFX
including sequential therapy in the 29 patients with
severe UC was 65.5% (19/29). The colectomy rate at
8 weeks was 3.4% (1/29).
Long-term outcomes
Of the 29 patients with severe UC, 25 were followed up
for more than 6 months after initiating treatment with
TAC or IFX. The median follow-up period of the 25
patients (TAC group: n=19, IFX group: n=6) was
29 months (range 7–118 months). The clinical course of
long-term outcomes of the 25 patients with severe UC is
shown in ﬁgure 1. Of 14 patients who achieved a CR at
8 weeks after initiating TAC, 11 could maintain a CR
continuing TAC. The remaining three had a ﬂare-up of
UC, of whom one resulted in colectomy without sequen-
tial therapy within 6 months after initiating TAC. The
remaining two patients who had a ﬂare-up of UC
despite achieving a CR and six patients who could not
achieve a CR at 8 weeks after initiating TAC required
sequential therapy (switched to IFX). After induction of
sequential therapy, six of the eight patients could
achieve and maintain a CR, and the remaining two
required colectomy. Moreover, two patients who
required the sequential therapy (switched to IFX) within
8 weeks after initiating TAC could not achieve a CR and
required colectomy. However, in the IFX group, three of
the four patients who achieved a CR at 8 weeks after ini-
tiating IFX could maintain a CR. The remaining one
patient who had a ﬂare-up of UC and the one patient
who could not achieve a CR at 8 weeks after initiating
IFX required sequential therapy (switched to TAC), and
they could achieve and maintain a CR. The patient who
required sequential therapy (switched to TAC) within
8 weeks after initiating IFX could achieve and maintain
a CR. Overall, total 23 patients (TAC group: n=17, IFX
group: n=6) could maintain a CR at the end of
follow-up. The medications in these patients are sum-
marised in table 2. Regarding their maintenance
therapy at the end of follow-up, ﬁve patients in the TAC
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Table 1 Clinical characteristics of 29 patients with severe UC
All patients Tacrolimus group Infliximab group
p Value*(n=29) (n=22) (n=7)
Age at diagnosis of severe UC (median (range)) (years) 34 (19–69) 34.5 (19–69) 33 (22–58) 0.799
Disease duration prior to the induction therapy (median (range)) (months) 43 (2–348) 45 (2–348) 32 (6–157) 0.760
Follow-up period (median (range)) (months) 27 (0.5–118) 21 (2–118) 30 (0.5–79) 0.541
Gender 0.758
Male 18 14 4
Female 11 8 3
Hospitalised patients at the induction therapy 24 19 5 0.569
Partial Mayo score (median (range)) 9 (8–9) 8.5 (8–9) 9 (8–9) 0.779
Endoscopic Mayo score (median (range)) 3 (2–3) 3 (3–3) 3 (2–3) 0.476
Disease extent 0.555
Extensive 23 18 5
Left sided 6 4 2
Laboratory examination (mean±SD (range)) (mg/dL)
C reactive protein 7.0±7.1 (0.1–27.1) 5.7±5.5 (0.1–19) 11.2±10.3 (1.3–27.1) 0.270
Haemoglobin 10.3±1.8 (7.1–13.4) 10.4±2.0 (7.1–13.4) 10.0±1.1 (9.3–12.5) 0.858
Albumin 2.9±0.6 (1.7–4.0) 2.9±0.6 (1.8–4.0) 2.8±0.7 (1.7–3.7) 0.939
Previous response to corticosteroid
Corticosteroid refractory 14 12 2 0.436
Corticosteroid dependent 11 6 5 0.096
Corticosteroid naïve 4 4 0 0.544
Concomitant therapy at the induction therapy†
5-aminosalitirate 28 21 7 1.000
Corticosteroid 16 12 4 1.000
Thiopurine 9 6 3 0.746
Cytapheresis 15 13 2 0.323
Positive rate of CMV reactivation (percentage (positive/all)) (%) 44.8 (13/29) 40.9 (9/22) 57.1 (4/7) 0.452
Numbers of patients are shown unless specified.
*Comparison of differences between tacrolimus group and infliximab group was evaluated.
†Some patients were treated in conjunction with other therapies.
























group and one patient in the IFX group were treated
with IFX in conjunction with IM and 5-ASA. One
patient in the TAC group and two patients in the IFX
group were treated with IFX in conjunction with 5-ASA.
Three patients in the TAC group were treated with TAC
in conjunction with IM and 5-ASA. Four patients in the
TAC group and two patients in the IFX group were
treated with IM and 5-ASA. One patient in the TAC
group was treated with IM alone due to intolerance of
5-ASA. Three patients in the TAC group and one patient
in the IFX group were treated with 5-ASA. Regarding
cumulative dosage of each drug during the observa-
tional period, the mean cumulative dosage of IM in the
TAC group was more than twice that in the IFX group.
Comparison of maintenance therapy between the patients
who achieved a CR with TAC and those who relapsed
with TAC
Of the 29 patients with severe UC, 25 (22 in the TAC
group and 3 in the IFX group) were treated with TAC in
their clinical course. We analysed the differences in the
maintenance therapy between those who achieved a CR
with TAC (CR group, n=14) and those who relapsed
with TAC (Relapse group, n=11), as shown in table 3. In
the 18 patients (10 in the CR group and 8 in the
Relapse group), long-term use of TAC (more than
6 months) was performed. As a result, 10 of 18 patients
(55.6%) could achieve a CR. Regarding the mainten-
ance therapy with TAC, the median treatment duration
with TAC was 471 days (range 325–995 days) in the 10
patients who were ﬁnally switched to IM or treated with
the combination of TAC and IM.
Intensification of IFX treatment
Of the 29 patients with severe UC, 17 patients (10 in the
TAC group and 7 in the IFX group) were treated with at
least more than one infusion of IFX. Nine (6 in the TAC
group and 3 in the IFX group) of the 17 patients could
achieve a CR after the treatment with IFX. Six (4 in the
TAC group and 2 in the IFX group) of the nine patients
needed the intensiﬁcation of IFX treatment such as
dose escalation and shortening of interval in order to
maintain a CR. All the eight patients (4 in the TAC
group and 4 in the IFX group) who could not achieve a
CR from the treatment with IFX resulted in colectomy
or were switched to TAC without intensifying IFX
treatment.
Mucosal healing
During our observational periods, 27 of the 29 patients
were evaluated by colonoscopy after their treatments,
although the timing and frequency of colonoscopy
varied among the patients. At the ﬁrst endoscopic ana-
lysis after the initial treatment (median: 31 days, range:
9–1782 days), four patients in the TAC group could
achieve mucosal healing. Two of the four patients had
been continued with TAC treatment at the ﬁrst endo-
scopic examination and the remaining two patients had
Figure 1 Short-term and long-term outcomes of the 29 patients with severe ulcerative colitis (UC). Short-term outcomes: 14 of
22 patients in the tacrolimus (TAC) group and 5 of 7 patients in the infliximab (IFX) group achieved a clinical remission (CR) at
8 weeks after initiating TAC or IFX. Two patients in the TAC group were refractory to TAC and required sequential therapy. Two
patients in the IFX group were refractory to IFX and one could achieve a CR after switching to TAC. The remaining one resulted
in colectomy without switching to TAC. The CR rate at 8 weeks in the TAC and IFX groups was 63.6% and 71.4%, respectively.
Long-term outcomes: In the TAC group, of 14 patients who achieved a CR at 8 weeks after initiating TAC, 11 patients could
maintain a CR and 3 flared-up. A total of nine patients could not achieve and maintain a CR with TAC. Six of the nine patients
could achieve a CR by sequential therapy, and the remaining three resulted in colectomy (one patient within 6 months). Two
patients who required sequential therapy within 8 weeks after initiating TAC resulted in colectomy within 6 months after initiating
TAC. In the IFX group, of four patients who achieved a CR at 8 weeks after initiating IFX, three could maintain a CR and one
flared-up. A total of two patients could not achieve and maintain a CR with IFX and they could achieve a CR by sequential
therapy. One patient who achieved a CR by sequential therapy within 8 weeks after initiating IFX could maintain a CR. *Reveals
the patient who resulted in colectomy within 6 months after initiating TAC or IFX.
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not. At the latest endoscopic analysis after the initial
treatment (median: 851 days, range: 248–2091 days),
seven patients could achieve mucosal healing. One of
the seven patients could achieve a CR after switching
IFX to TAC and the remaining six patients could achieve
a CR after treatment with TAC.
Colectomy-free survival
Of the 29 patients with severe UC, 6 patients required
colectomy. One resulted in colectomy within 8 weeks
after initiating IFX and 3 resulted in colectomy within
6 months after initiating TAC. The remaining two
resulted in colectomy later than 6 months after initiating
TAC. Based on Kaplan-Meier survival analysis, the overall
cumulative colectomy-free survival was estimated to be
79.3% at 118 months (ﬁgure 2A). Moreover, the cumula-
tive colectomy-free survival was 77.3% at 118 months
(range 2–118 months) in the TAC group and 85.7% at
79 months (range 0.5–79 months) in the IFX group
(p=0.704; ﬁgure 2B). Regarding the effect of the
sequential therapies, 9 of 13 patients who were refractory
to the initial treatments (TAC group: n=10, IFX group:
n=3) responded to the sequential therapies and avoided
colectomy.
Predictors of colectomy
To evaluate the predictive factors for colectomy in
patients with severe UC, we analysed the differences in
the patient characteristics between patients with severe
UC who required a colectomy (colectomy group) and
those who did not (non-colectomy group; table 4). The
positive rate of CMV reactivation in the colectomy group
was signiﬁcantly higher than that in the non-colectomy
group (p=0.033). There were no signiﬁcant differences
between the colectomy group and non-colectomy group
with regard to age, disease duration, sex, partial Mayo
score, endoscopic Mayo score, disease extent, laboratory
examination, daily dosage of CS and copy number of
CMV-DNA. Therefore, our data suggest that positivity of
colonic CMV reactivation is a predictive factor for colec-
tomy, regardless of the copy number of CMV-DNA in
the colonic mucosa.
Adverse events
During our observational periods, no patients died and
no life-threatening events occurred. In addition, oppor-
tunistic infections and reactivation of tuberculosis or
hepatitis B virus were not observed in any of the 29
patients with severe UC.
Table 2 Medications in patients who achieved a CR at the end of follow-up
TAC group IFX group
(n=17) (n=6)
Observational period (median (range)) (months) 29 (14–118) 32 (22–79)







Cumulative dosage of each drug during observational period
TAC (mean (range)) (mg) 2852 (389–5937) 1016 (0–2861)
IFX (mean (range)) (mg) 3866 (1500–19 260) 5843 (225–20 520)
IM (mean (range)) (mg) 38 910 (7800–110 550) 16 122 (0–42 700)
5-ASA (mean (range)) (g) 4537 (0–10 138) 3609 (828–6994)
Numbers of patients are shown unless specified.
5-ASA, 5-aminosalicylate; CR, clinical remission; IFX, infliximab; IM, immunomodulators; TAC, tacrolimus.




Duration of TAC use (median (range)) (days) 411 (121–995) 405 (63–962)
Cessation of TAC within 6 months 4 3




Numbers of patients are shown unless specified.
5-ASA, 5-aminosalicylate; CR, clinical remission; IM, immunomodulators; TAC, tacrolimus.
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DISCUSSION
The purpose of this retrospective study was to evaluate
the short-term and long-term clinical outcome of
Japanese patients with severe UC treated with TAC, IFX
and sequential therapies. The rate of induction of remis-
sion at 8 weeks in the TAC and IFX groups was similar.
In addition, 69.2% (9/13) of patients required alterna-
tive induction regimens (so-called sequential therapies)
to avoid colectomy. During this observational study, no
serious complications related to these medical therapies
were observed. The present data ﬁrst suggest that
sequential therapies could avoid colectomy in cases of
severe UC failing to respond to TAC or IFX.
Patients with severe UC require a pro-active approach
with either effective medical treatment or a timely surgi-
cal approach. To avoid the increasing mortality of these
patients, physicians should carefully determine the
therapeutic strategy depending on the patient’s condi-
tion. Intravenous CS remains the ﬁrst-line treatment.23 24
High-dose and prolonged exposure to CS, however,
predisposes patients to increased infections and peri-
operative complications such as thrombosis and anasto-
motic leakage.25 Thus, in patients with severe UC who
did not respond to CS therapies, rescue medical therap-
ies with either a calcineurin inhibitor or antitumour
necrosis factor α antibodies are necessary.
First, we assessed the rate of induction of remission in
patients with severe UC treated with TAC or IFX.
Regarding the effect of IFX in hospitalised patients with
severely active UC, two randomised control trials (RCTs)
evaluated 56 patients and compared biological therapy
with placebo. According to these RCTs, IFX tended to be
superior to placebo.26 27 As for the efﬁcacy of TAC in
severely active UC, previous reports showed that CR rates
in patients with severe UC at 1 and 3 months after admin-
istering TAC were 45% and 72%, respectively.9 28 Our
study demonstrated that there were no differences in the
CR rates in patients with severe UC at 8 weeks between
the TAC and IFX groups, suggesting that the effects of
TAC, a calcineurin inhibitor, are potentially similar to
those of IFX on severe UC. Actually, recent RCTs revealed
that the efﬁcacies of CsA, another calcineurin inhibitor,
were equivalent to those of IFX for acute patients with
severe UC refractory to intravenous CS.29
Second, we assessed the efﬁcacy and safety of sequential
therapies in this study. Several studies have examined the
effect of sequential therapy with alternative drugs in
patients with refractory UC.13 14 30–32 Maser et al reported
the efﬁcacy of the sequential therapies in patients with UC
refractory to CsA or IFX. The CR rate of the IFX-salvage
group (CsA-patients with refractory UC treated with IFX)
and the CsA-salvage group (IFX-refractory those with CsA)
was 40% and 33%, respectively.32 In the present study, the
CR rate of the IFX-salvage group (TAC-refractory, receiving
IFX) and the TAC-salvage group (IFX-refractory, receiving
TAC) was 60% (6/10) and 100% (3/3), respectively. Of
note, all patients requiring sequential therapies had no
serious adverse events. Maser’s data,32 however, showed a
high incidence (16%, 3/19) of serious adverse events,
including one death related to infection. The different fre-
quency of serious side effects between our study and
Maser’s might be due to different doses of CS with which
patients in each study had been treated before starting cal-
cineurin inhibitor or biologicals.33 However, gastroenterol-
ogists must deliberately follow-up patients with UC treated
with sequential therapies to avoid adverse events as much
as possible. Several studies have reported the long-term
outcomes of patients with severe CS-refractory UC treated
with CsA or IFX. Croft et al34 reported that the colectomy-
free rate at 12 months was 42% in the CsA group and 65%
in the IFX group. The 3-year colectomy-free rates ranged
from 43% to 55% in the CsA group, and from 70% to 73%
in the IFX group.35–37 In our study, the cumulative
colectomy-free survival was 77.3% at 118 months in the
TAC group and 85.7% at 79 months in the IFX group
(ﬁgure 2B). Thus, sequential therapies appeared to con-
tribute to extending the colectomy-free survival term.
Figure 2 (A) Proportion of patients who avoided colectomy
(n=23). The overall cumulative colectomy-free survival was
estimated to be 79.3% at 118 months, based on Kaplan-Meier
survival analysis. (B) Proportion of patients who avoided
colectomy (n=17 in the tacrolimus (TAC) group and n=6 in the
infliximab (IFX) group). The cumulative colectomy-free
survival was estimated to be 77.3% at 118 months in the TAC
group (solid line) and 85.7% at 79 months in the IFX group
(dashed line) (p=0.704).
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Moreover, the maintenance therapy, particularly after the
induction therapy with TAC in severe UC, is an important
issue to prevent colectomy. According to our study, long-
term treatment with TAC could induce a clinically better
outcome in patients with severe UC. However, further
studies will be required to ascertain the efﬁcacy and safety
levels of long-term treatment with TAC in patients with
refractory UC.
Next, we analysed the predictors of colectomy in
this study. Our data demonstrated that positivity of
CMV-DNA in the colonic mucosa was a signiﬁcant pre-
dictor of colectomy. In general, CMV can lead to worsen-
ing colitis in patients with moderate-to-severe UC.38 39
Therefore, we always consider the involvement of CMV
infection in patients with UC refractory to immunosup-
pressive therapies. We assessed the CMV-DNA in the
colonic mucosa of all enrolled patients before starting
TAC or IFX therapy. In the present study, however, there
was no signiﬁcant difference in the copy number of
CMV-DNA between the two groups. Heterogeneity of
patients’ characteristics might affect these discrepancies.
Therefore, the relevance of the copy number of
CMV-DNA is an issue to be addressed in the future. Of 13
patients who were positive for colonic CMV-DNA, 7
patients were treated with ganciclovir on the basis of phy-
sician’s decision. The use of ganciclovir did not affect col-
ectomy rate in this retrospective observational study
(p=0.12, data by χ2 analysis). Because there was no differ-
ence in the CR ratio at 8 weeks between the two groups,
our data suggest that optimal control of colonic inﬂam-
mation could lead to UC remission despite the lack of
antiviral therapy.
There are some limitations to our study, including the
small sample size, heterogeneity of patients’ prior treat-
ment history and therapeutic protocol. Despite the small
number of patients, our data suggested the efﬁcacy of
sequential therapies for avoiding colectomy in patients
with severe UC. However, the difference in the history of
patients’ prior treatments might have affected subse-
quent treatment outcome. Moreover, because this study
was a retrospective uncontrolled study, our current data
should be assessed carefully.
CONCLUSIONS
In conclusion, our data indicate that TAC, IFX and their
sequential therapies could allow some patients with
severe UC to avoid colectomy, although further investiga-
tion with larger cases is necessary.
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